 |
市場調查報告書
商品編碼
1608706
遺傳性血管性水腫市場：按類型、按藥物類別、按給藥途徑、按分銷管道、按地區Hereditary Angioedema Market By Type, By Drug Class, By Route of Administration, By Distribution Channel, By Geography |
||||||
遺傳性血管水腫市場預計 2024 年為 28.6 億美元，預計到 2031 年將達到 53.6 億美元，2024 年至 2031 年複合年成長率為 9.4%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年 | 2023年 | 市場規模（2024年） | 28.6億美元 |
| 實際資料 | 2019-2023 | 預測期 | 2024-2031 |
| 預測期複合年成長率（2024-2031）： | 9.40% | 預計金額（2031年） | |
遺傳性血管性水腫是一種罕見的遺傳性疾病，其特徵是反覆出現嚴重的皮下或黏膜下水腫。症狀包括手、腳、四肢、臉部、腸道和呼吸道腫脹。這種情況是由 C1 抑制劑水平下降或功能下降引起的，C1 抑制劑是一種控制補體和纖溶系統某些部分的血清蛋白。遺傳性血管性水腫患者平均每四週至少出現一次水腫，通常需要醫療介入來控制症狀。這種疾病的全球盛行率不斷增加，以及人們對現有治療方案的認知不斷提高，可能會推動遺傳性血管水腫市場的成長。
市場動態
對替代治療方法的研究不斷增加、全球 HAE 盛行率上升、 FDA認證核可藥的可用性以及對該疾病的認知不斷提高可能會推動遺傳性血管水腫市場的成長。然而，與HAE治療相關的高成本和新興市場的認知度低可能會阻礙市場開拓。皮下注射C1-INH產品和口服療法的開拓為市場參與者提供了新的機會。
本研究的主要特點
該報告對全球遺傳性血管水腫市場進行了詳細分析，並提供了以2023年為基準年的預測期（2024-2031年）的市場規模和年複合成長率（CAGR%）。
它還揭示了各個細分市場的潛在商機，並說明了該市場有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。
根據公司亮點、產品系列、主要亮點、績效和策略等參數對全球遺傳性血管水腫市場的主要參與者進行了分析。
主要公司包括 CSL Behring、賽諾菲、工業、Orchard Therapeutics plc.、Pharming Group NV、BioCryst Pharmaceuticals, Inc.、Ionis Pharmaceuticals, Inc.、Attune Pharmaceuticals、Arrowhead Pharmaceuticals, Inc.、Adverum Biotechnotical, Incceuticals、Arrowhead Pharmaceuticals, Inc.、Adverum Biotechnotical, Inc. 、CENTOGENE NV等
該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。
全球遺傳性血管水腫市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
透過用於分析全球遺傳性血管水腫市場的各種策略矩陣，將促進相關人員的決策。
目錄
第1章 分析目的與前提
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
第3章市場動態、法規與趨勢分析
- 市場動態
- 影響分析
- 主要亮點
- 監管場景
- 產品發布/核准
- PEST分析
- 波特的分析
- 企業合併(M&A) 場景
- 流行病學
第 4 章 遺傳性血管水腫市場：按類型分類，2019-2031 年（十億美元）
- 遺傳性血管性水腫 I 型
- 遺傳性血管性水腫 II 型
第5章 遺傳性血管水腫市場：依藥物類別分類，2019-2031 年（十億美元）
- C1酯酶抑制劑
- 激肽釋放酶抑制劑
- 緩激肽受體
- 減毒雄激素
- 其他
第6章 遺傳性血管水腫市場：依給藥途徑分類，2019-2031 年（十億美元）
- 皮下的
- 口服
第 7 章 遺傳性血管水腫市場：依通路分類，2019-2031 年（十億美元）
- 醫院藥房
- 零售藥房
- 網路藥房
第 8 章 遺傳性血管水腫市場：按地區分類，2019-2031 年（十億美元）
- 北美洲
- 拉丁美洲
- 歐洲
- 亞太地區
- 中東
- 非洲
第9章 競爭格局
- CSL Behring
- Sanofi
- Takeda Pharmaceutical Company Limited
- Orchard Therapeutics plc.
- Pharming Group NV
- BioCryst Pharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc.
- Attune Pharmaceuticals
- Arrowhead Pharmaceuticals, Inc.
- Adverum Biotechnologies, Inc.
- KalVista Pharmaceuticals
- CENTOGENE NV
第10章分析師建議
- 命運之輪
- 分析師觀點
- 一致的機會圖
第11章 參考文獻與調查方法
- 參考
- 調查方法
- 關於出版商
Hereditary angioedema market is estimated to be valued at USD 2.86 Bn in 2024 and is expected to reach USD 5.36 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 9.4% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | 2.86 Bn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2024 to 2031 CAGR: | 9.40% | 2031 Value Projection: | 5.36 Bn |
Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of intense subcutaneous or submucosal edema. Symptoms include episodes of swelling in the hands, feet, limbs, face, intestinal tract and airway. The episodes are caused by decreased levels or functioning of C1 inhibitor, which is a serum protein responsible for regulating certain parts of the complement and fibrinolytic systems. Patients with hereditary angioedema experience episodes of edema at least once every 4 weeks on average and commonly require medical intervention for symptom management. Increasing prevalence of disease globally and rising awareness about available treatment options can drive the hereditary angioedema market growth.
Market Dynamics
Increasing research into treatment alternatives, rising prevalence of HAE globally, availability of FDA approved drugs and growing awareness about the disease can drive the hereditary angioedema market growth. However, high costs associated with HAE therapies and lack of awareness in developing countries can hamper the market growth. Development of subcutaneous C1-INH products and oral treatments offers new opportunities for the market players.
Key features of the study
This report provides in-depth analysis of the global hereditary angioedema market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global hereditary angioedema market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include CSL Behring, Sanofi, Takeda Pharmaceutical Company Limited, Orchard Therapeutics plc., Pharming Group N.V., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Attune Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., KalVista Pharmaceuticals, and CENTOGENE N.V.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global hereditary angioedema market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hereditary angioedema market
Market Segmentation
- By Type Insights (Revenue, USD Bn, 2019 - 2031)
- Hereditary Angioedema Type I
- Hereditary Angioedema Type II
- By Drug Class Insights (Revenue, USD Bn, 2019 - 2031)
- C1 Esterase Inhibitor
- Kallikrein Inhibitor
- Bradykinin Receptor
- Attenuated Androgens
- Others
- By Route of Administration Insights (Revenue, USD Bn, 2019 - 2031)
- Subcutaneous
- Intravenous
- Oral
- By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Regional Insights (Revenue, USD Bn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- CSL Behring
- Sanofi
- Takeda Pharmaceutical Company Limited
- Orchard Therapeutics plc.
- Pharming Group N.V.
- BioCryst Pharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc.
- Attune Pharmaceuticals
- Arrowhead Pharmaceuticals, Inc.
- Adverum Biotechnologies, Inc.
- KalVista Pharmaceuticals
- CENTOGENE N.V.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Hereditary Angioedema Market, By Type
- Hereditary Angioedema Market, By Drug Class
- Hereditary Angioedema Market, By Route of Administration
- Hereditary Angioedema Market, By Distribution Channel
- Hereditary Angioedema Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Epidemiology
- Pipeline Analysis
4. Hereditary Angioedema Market, By Type, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Hereditary Angioedema Type I
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Hereditary Angioedema Type II
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
5. Hereditary Angioedema Market, By Drug Class, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- C1 Esterase Inhibitor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Kallikrein Inhibitor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Bradykinin Receptor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Attenuated Androgens
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
6. Hereditary Angioedema Market, By Route of Administration, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
7. Hereditary Angioedema Market, By Distribution Channel, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
8. Hereditary Angioedema Market, By Region, 2019 - 2031, (USD Bn)
- Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2020 - 2031, (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country/Region, 2019 - 2031, (USD Bn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- CSL Behring
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Orchard Therapeutics plc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pharming Group N.V.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BioCryst Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ionis Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Attune Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Arrowhead Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Adverum Biotechnologies, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- KalVista Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- CENTOGENE N.V.
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
